Clinical Trial Update: Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Withdrawal notice for a Phase 1/Phase 2 trial of Niraparib with selenium in BRCA-negative, platinum-resistant fallopian tube, ovarian, and primary peritoneal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Niraparib (Niraparib)
• Selenium (selenium)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN